Bentonite-Vancomycin Composition for Low-Dose CDI Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for Clostridioides difficile infection (CDI) rely heavily on antibiotics, which can be resistant and cause significant side effects, necessitating a more effective and less toxic approach.
Innovation Solution
A pharmaceutical composition comprising a clay mineral complex of smectite-based minerals, particularly bentonite, combined with vancomycin, is developed to synergistically treat CDI, reducing antibiotic usage and side effects through a method involving suspension preparation, mixing, centrifugation, and freeze-drying.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat CDI, then antibacterial effect is improved, but side effects and antibiotic resistance increase
Solution Approach 1:
The patent combines vancomycin (antibiotic) with bentonite (clay mineral) to form a composite pharmaceutical composition. This merging allows the antibiotic to maintain its antibacterial effect while the bentonite component reduces side effects and prevents antibiotic resistance, thus resolving the contradiction between efficacy and harmful effects
Solution Approach 2:
The invention creates a composite material consisting of vancomycin and bentonite in specific ratios (1:4 to 1:6 by weight). This composite structure enables the antibiotic to function effectively while the clay mineral matrix reduces systemic exposure and harmful effects, addressing both the need for antibacterial activity and the reduction of side effects
2Reliability
If high doses of antibiotics are used to treat CDI, then therapeutic effect is improved, but side effects increase
Solution Approach 1:
The patent changes the dosage parameters by using lower amounts of vancomycin (125-500 mg) combined with specific amounts of bentonite (500-2000 mg). This parameter optimization maintains therapeutic effect while reducing side effects, as the clay mineral allows for reduced antibiotic dosing
3Reliability
If high doses of bentonite are used to remove toxins, then toxin removal effect is improved, but treatment amount increases
Solution Approach 1:
The patent merges vancomycin and bentonite in optimized ratios (1:4 to 1:6 by weight), where the antibiotic handles bacterial elimination and the clay mineral handles toxin removal. This synergistic combination allows each component to work at lower doses than would be required individually, reducing the total treatment amount while maintaining effective toxin removal
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves effective CDI treatment with significantly lower amounts of antibiotics and bentonite, enhancing therapeutic outcomes while minimizing side effects.
Implementation Method 1
smectite, which is used as a therapeutic agent for colitis accompanied by diarrhea and uses bentonite as a main component, is effective in removing the toxin of C. difficile
Implementation Method 2
a method for producing the same
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a pharmaceutical composition for treating Clostridioides difficile Infection (CDI), and a method for producing same. The pharmaceutical composition comprises a complex of clay minerals, such as bentonite, and antibiotics, such as vancomycin. Accordingly, the pharmaceutical composition has an excellent treatment effect on CDI even with a significantly smaller amount of each of the existing antibiotics and clay minerals than the maximum recommended daily intake thereof, and has the effect of reducing side effects that can be caused by the massive intake of the antibiotics and clay minerals.